替罗非班应用于急性心肌梗死介入治疗的临床效果分析

Evaluation on the efficacy of tirofiban in patients with acute myocardial infarction rreated by primary percutaneous coronary intervention

目的探讨分析替罗非班在急性心肌梗死介入治疗中的临床疗效。方法选取本院2010年11月--2012年6月收治的164例急性心肌梗死患者，按照知情同意原则将患者随机分为对照组和治疗组各82例，其中对照组采用阿司匹林、氯吡格雷和肝素的常规冠状动脉介入治疗方法（PCD治疗，而治疗组则在对照组常规（PCI）治疗的基础上进行替罗非班介入治疗。分析两组患者的临床情况。结果对照组和治疗组比较，治疗组达到Ⅲ级TIMI的患者例数明显多于对照组（P〈0．05），患者的左心室射血分数（LVEF）明显改善和住院时间缩短（P〈0．05），且治疗组患者的心脏不良事件发生率各监测阶段均低于对照组（P〈0．05）。结论替罗非班可减缓急性心肌梗死患者病症，具有重要的临床推广价值。

Objective To evaluate the efficacy of tirofiban in patients with acute myocardial infarction treated by pri- mary percutaneous coronary intervention. Methods One hundred and sixty-four patients with acute myocardial infarc- tion from November 2010 to June 2012 in our hospital were randolnly divided into the treatment group and the control group, according to informed consent principle, 82 patients respectively. The patients for control group were treated with aspirin, clopidogrel and injected heparin. The treatment group patients were used tirofiban by ventricular injection fraction. The efficacy was analysed between the two groups. Results Compared with control group, the patients to m at the thrombolysis inmyocardial infarction after treatment in the treatment group were more （P 〈 0. 05）; Left ventricular ejection fraction （LEVF） was improved, and the hospitalization time in the treatment group was shorten （P 〈 0.05）. Ma- jor adverse cardiac events （MACE） during hospitalization period showed lower in the treatment group （P 〈 O. 05）. Con- clusion Adjunctive therapy undergoing emergent PCI can apply effectively the tirofiban for the patients with acute my- ocardial infarction, which is worthy of spreading widely.